Severity of Alopecia Tool (SALT) Calculator
Use this clinical tool to calculate the Severity of Alopecia Tool (SALT) score and objectively quantify the extent of scalp hair loss in patients with alopecia areata. By mathematically weighting the percentage of active hair loss across four distinct anatomical quadrants of the scalp, this calculator produces a standardized composite score. This validated tool is the international gold standard used to establish baseline disease severity, track hair regrowth velocities, and satisfy insurance or regulatory criteria for initiating advanced target therapies, such as Janus kinase (JAK) inhibitors.
The Pathophysiology and Clinical Role of SALT Scoring
Alopecia areata is a common, tissue-specific autoimmune disease characterized by the sudden, non-scarring loss of hair. The core pathological driver is the collapse of the immune privilege naturally maintained by healthy hair follicles. Under normal physiological conditions, hair follicles suppress the expression of major histocompatibility complex (MHC) class I molecules to protect developing hair fiber cells from auto-aggressive surveillance.
In alopecia areata, local up-regulation of interferon-gamma breaks this barrier, forcing the aberrant presentation of follicular autoantigens. This triggers an aggressive, dense lymphocytic infiltrate—predominantly composed of CD8+ cytotoxic T cells—around the active growth hair bulb, causing premature follicular regression into the resting phase and causing patchy or total shedding.
The presentation of alopecia areata is highly unpredictable, varying from localized patches to complete loss of all scalp hair (Alopecia Totalis) or universal body hair loss (Alopecia Universalis). Because visual overestimations of random patches are notoriously inaccurate, clinicians require a reliable, structured method to document the physical baseline. Developed by the National Alopecia Areata Foundation investigator guidelines, the SALT score standardizes visual assessment by treating the scalp as a geometric model. This system replaces subjective classification with a rigorous percentage model, providing the objective framework needed to track real-world hair regrowth and guide systemic immunomodulatory treatment cascades.
Scoring Architecture and Mathematical Breakdown
Calculating a SALT score requires the clinician to inspect the patient's scalp from multiple angles and assign a raw hair loss percentage (from 0% to 100%) within four separate anatomical quadrants. Each quadrant is pre-weighted according to its mathematically mapped proportion of total human scalp surface area:
Vertex / Top of Scalp: Represents 40% (0.40) of total scalp surface area.
Posterior / Back of Scalp: Represents 24% (0.24) of total scalp surface area.
Right Profile / Right Side: Represents 18% (0.18) of total scalp surface area.
Left Profile / Left Side: Represents 18% (0.18) of total scalp surface area.
The Final Composite Formula
The percentage of hair loss estimated in each quadrant is multiplied by its respective weighting coefficient, and the four values are aggregated to yield the final total score:
Total SALT Score = (0.18 x Right Side Percentage) + (0.18 x Left Side Percentage) + (0.40 x Top Percentage) + (0.24 x Back Percentage)
The composite score ranges continuously from 0 to 100, where 0 indicates perfect, full scalp hair coverage and 100 represents absolute, complete scalp hair loss.
Clinical Interpretation and Treatment Thresholds
The absolute calculated SALT score maps directly into validated clinical severity categories under the Alopecia Areata Investigator's Global Assessment framework:
Score 0 (None): Zero active scalp hair loss.
Score 1 to 20 (Limited / Mild Disease): Localized, small patches. Typically managed with first-line conservative interventions, such as high-potency topical corticosteroids, intralesional triamcinolone acetonide injections directly into active borders, or topical minoxidil.
Score 21 to 49 (Moderate Disease): Multiple patches or larger expanding confluent zones. This represents a crucial clinical boundary where systemically active interventions or systemic phototherapy are often considered to halt rapid multi-quadrant progression.
Score 50 to 94 (Severe Disease): Extensive, widespread scalp involvement.
Score 95 to 100 (Very Severe Disease): Near-total (Alopecia Totalis) or absolute, complete hair loss across the entire scalp area.
Regulatory Milestones:
In modern clinical dermatology, a baseline SALT score of 50 or more defines severe alopecia areata. To satisfy contemporary regulatory approval and insurance guidelines for advanced targeted oral therapies (such as the JAK inhibitors Ritlecitinib or Baricitinib), the standard primary efficacy target is for the patient to achieve an absolute SALT score of 20 or less (representing 80% or more scalp hair coverage) at the evaluation endpoint.
Efficacy is also tracked chronologically via percentage-reduction thresholds relative to the patient's specific baseline score:
SALT 50: 50% or more reduction from baseline score, indicating a clinically meaningful early response.
SALT 90 / SALT 100: 90% or 100% reduction from baseline, representing near or absolute complete regrowth.
Important Clinical Nuances and Assessment Pitfalls
To ensure the accurate application of the SALT score in longitudinal records, providers must navigate several clinical limitations and edge cases:
The Face and Body Blind Spot: The standard SALT protocol focuses exclusively on scalp surface area. It completely fails to capture the severe functional and psychological impact of losing the eyebrows, eyelashes, beard, or general body hair. A patient can present with a low scalp SALT score (such as 15) but suffer profound distress due to total eyebrow and eyelash loss. In these instances, clinicians should cross-reference the score with comprehensive indices like the Alopecia Areata Scale or the Alopecia Areata Severity and Morbidity Index.
Excluding Exogenous Regrowth / Vellus Hair: When visually inspecting a quadrant, the clinician must distinguish between true terminal hair coverage and fine, downy, unpigmented vellus hair (early regrowth). Counting fine vellus hairs as full, normal hair density can artificially underestimate the active SALT score, potentially tracking a false trend of early treatment success before the hair has functionally converted to stable terminal fibers.
The Diffuse Incognito Paradox: The standard visual quadrant model is optimized for distinct, patchy hair loss. In the less common diffuse variant of alopecia areata (Alopecia Areata Incognita), hair loss occurs as a uniform, widespread thinning across all four quadrants simultaneously rather than in distinct circular patches. Visual estimation of percentage loss in diffuse cases is highly subjective and error-prone, making baseline standardized photography or digital phototrichograms essential to verify accuracy.
Evaluating Disease Activity vs. Static Loss: A static SALT score across multiple months implies structural disease stability. However, the score does not measure real-time velocity. Clinicians must always perform a peripheral Hair Pull Test at the margins of active patches alongside the calculation. A positive pull test (exhibiting multiple dystrophic, exclamation-mark telogen hairs) indicates a highly unstable, actively expanding flare that mandates immediate systemic stabilization therapy, regardless of whether the current numerical SALT score is low or high.
References
Olsen, E. A., Hordinsky, M. K., Price, V. H., Roberts, J. L., Shapiro, J., Canfield, D., and National Alopecia Areata Foundation. (2004). Alopecia areata investigational assessment guidelines part II. Journal of the American Academy of Dermatology, 51(3), 440-447.
Olsen, E. A., and Canfield, D. (2016). SALT II: A new take on the Severity of Alopecia Tool (SALT) for determining percentage scalp hair loss. Journal of the American Academy of Dermatology, 75(6), 1268-1270.
King, B., Ohyama, M., Kwon, O., et al. (2022). Two phase 3 trials of Baricitinib for Alopecia Areata. New England Journal of Medicine, 386(19), 1803-1816.
Got any Suggestion?
Contact:
info@histamind.com